Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (formerly Pluristem Life Systems, Inc.)
Filing Type: Form 8-K (Current Report)
Reporting Date: December 7, 2007 (Event Date: December 6, 2007)
Headquarters: Haifa, Israel
The registrant is a biotechnology company focused on stem cell therapies. This filing reports a significant corporate event regarding its stock listing status.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The document is strictly a notification of a corporate event.
Material Changes
- NASDAQ Listing Approval: The company received approval to list its common stock on the NASDAQ Capital Market.
- Trading Commencement: Trading is scheduled to begin on December 10, 2007, under the ticker symbol PSTI.
- Contingency Conditions: The listing is contingent upon the company remaining in compliance with all applicable listing standards on the trading start date. Specifically, the trading price of the common stock must remain at $4.00 or more. Failure to meet these standards may result in the rescission of the listing approval.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the listing approval but provides no forward-looking financial guidance or operational outlook beyond the listing event.
Risks and Contingencies:
- Price Maintenance Risk: The listing is conditional on the stock price maintaining a minimum of $4.00. A drop below this threshold prior to or on the trading start date could jeopardize the listing.
- Compliance Risk: The company must satisfy all other NASDAQ listing standards to maintain the approval.
Investor Verification Checklist
- Verify the stock price of PSTI on December 10, 2007, to confirm it met the $4.00 minimum requirement.
- Confirm the actual commencement of trading on the NASDAQ Capital Market under the symbol PSTI.
- Review the attached Press Release (Exhibit 99.1) for additional details on the company's strategic rationale for the listing.
- Check subsequent filings for any updates regarding the maintenance of NASDAQ listing standards.